Skip to main content
Premium Trial:

Request an Annual Quote

Biofield Licenses Rights to HPV Dx from ValiRx

NEW YORK (GenomeWeb News) – Biofield today said that it has licensed exclusive worldwide distribution rights, outside of Belgium, to ValiRx's human papillomavirus diagnostic test as well as its HyperGenomics and Nucleosomics cancer diagnostic products.

The products are being developed by ValiBio, a Belgian joint venture between the UK's ValiRx and the Institut de Pathologie et de Genetique, which houses ValiBio's operations.

The HPV test is being developed to detect infection by any of the known 15 high-risk HPV subtypes, according to ValiRx's website. The HyperGenomics platform includes differential diagnostic tests being developed for a variety of cancers, and the Nucleosomics platform includes non-invasive tests for detecting early cancer through epigenetic signal changes.

Philadelphia-based Biofield is developing its own diagnostic system for the early detection of breast cancer. The firm said that it aims to generate revenue from sales of this system to customers in foreign markets while acquiring other non-invasive detection and prevention technologies.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.